Dynacure Email Format
Biotechnology ResearchGrand Est, France11-50 Employees
Dynacure is a clinical-stage biotechnology company aiming to develop therapies for rare diseases with limited or no treatment options. Its leading program, DYN101, is an investigational antisense therapy intended to reduce dynamin 2 protein expression to treat Myotubular and Centronuclear Myopathies, developed in collaboration with Ionis Pharmaceuticals. The company is also advancing DYN201 for Hereditary Spastic Paraplegias and building a broader research portfolio targeting other orphan disorders. Headquartered in Strasbourg, France, with a corporate office in Philadelphia, Dynacure operates in the biotechnology research sector. In March 2023, the company announced a merger with Flamingo Therapeutics, reflecting a significant organizational development alongside its ongoing collaborations and development efforts.